Create a free research account to view current pricing and place an order.
Mechanism of action
CJC-1295 No DAC is a GHRH analog that stimulates pituitary GHRH receptors to promote pulsatile endogenous GH release. No-DAC versions are short acting and often timed around fasted or bedtime GH-axis windows.
Half-life & pharmacokinetics
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
100-300 mcg one to three times daily.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 100 mcg | 4 units |
| 200 mcg | 8 units |
| 300 mcg | 12 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 5 mg | 2 mL BAC Water | 0.025 mg/unit |
Injection timing
Often used before bed or during fasted windows to align with GH-axis signaling and reduce food-related interference.
Beginner escalation
Begin conservatively while monitoring hunger, edema, sleep quality, glucose response, and tingling/carpal-tunnel-like symptoms.
Side-effect mitigation
Monitor water retention, increased hunger, flushing, glucose variability, joint stiffness, or tingling. Periodic IGF-1 and glucose monitoring may be appropriate in longer protocols.
Stack compatibility
GH-axis agents stack most logically with complementary GH secretagogues; avoid overbuilding GH-axis stacks without monitoring IGF-1, glucose, and edema response.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
GH-axis protocols should reassess every 8-12 weeks: IGF-1, fasting glucose/A1c where appropriate, edema, sleep quality, hunger, body-composition objectives, and continued need.
Frequently asked questions
What is CJC-1295 No DAC and how does it work?
CJC-1295 No DAC is a GHRH analog that stimulates pituitary GHRH receptors to promote pulsatile endogenous GH release. No-DAC versions are short acting and often timed around fasted or bedtime GH-axis windows.
What is the half-life of CJC-1295 No DAC?
CJC-1295 No DAC: Short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
How is CJC-1295 No DAC reconstituted for research?
Preferred reconstitution for the 5 mg vial is 2 mL BAC Water, giving 0.025 mg/unit. Always confirm concentration math before any use. Research use only.
Is CJC-1295 No DAC FDA approved?
No. CJC-1295 No DAC is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration